XML 40 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Fair Value of Aggregate Merger Consideration (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended
Apr. 15, 2021
Jan. 31, 2020
Insight Merger Agreements [Member]    
Business Acquisition [Line Items]    
Cash consideration [1]   $ 7,000
Shares of Oncocyte common stock issued on the Merger Date [2]   1,915,692,000
Closing price per share of Oncocyte common stock on the Merger Date   $ 2.61
Market value of Oncocyte common stock issued   $ 5,000
Contingent Consideration [3]   11,130
Total fair value of consideration transferred on the Merger Date   $ 23,130
Chronix Biomedica lInc [Member]    
Business Acquisition [Line Items]    
Cash consideration $ 3,960  
Shares of Oncocyte common stock issued on the Merger Date 647,911  
Closing price per share of Oncocyte common stock on the Merger Date $ 5.09  
Market value of Oncocyte common stock issued $ 3,298  
Contingent Consideration 42,295  
Total fair value of consideration transferred on the Merger Date 50,103  
Settlement of Acquirer/Acquiree Activity Pre-Combination, net $ 550  
[1] The cash consideration paid on the Insight Merger Date was $6.4 million, which was net of a $0.6 million cash holdback discussed above, recorded as a holdback liability since Oncocyte retained the cash. In accordance with ASC 805, amounts held back for general representations and warranties of the sellers are included as part of the total consideration transferred.
[2] The 229,885 Stock Holdback shares were placed in an escrow account and considered to be issued and outstanding Oncocyte common stock. In accordance with ASC 805, amounts held back for general representations and warranties of the sellers, including escrowed shares of common stock, are included as part of the total consideration transferred.
[3] In accordance with ASC 805, Contingent Consideration, at fair value, is part of the total considered transferred on the Insight Merger Date, as further discussed below.